Product Details

CAT No.# CS-O-16987
Category Inhibitors
CAS 1448347-49-6
Molecular Weight 582.97
Molecular Formula C28H22ClF3N6O3
Purity: >98
Synonyms: 1448346-63-1; Ivosidenib, AG-120; AG120; AG 120; RG-120; RG 120; RG120; (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
References: Caino MC, Altieri DC. Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy. Clin Cancer Res. 2016 Feb 1;22(3):540-5. doi: 10.1158/1078-0432.CCR-15-0460. Review. PubMed PMID: 26660517; PubMed Central PMCID: PMC4738153. Chen J, Yang J, Cao P. The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors. Mini Rev Med Chem. 2016;16(16):1344-1358. PubMed PMID: 27292784.
Storage: 2-8 degree
COA / MSDS:    View COA    MSDS    Enquire
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
PEOPLE ALSO SEARCHED FOR: 1. 1-(2-(2-chloro-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)-4-methylpiperazine
2. (1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)
3. (E)-methyl 3-(3,5-difluoro-4-formylphenyl)acrylate
4. Rifabutin D6
5. Clindamycin Phosphate Sulfone trans-N-Oxide
6. loperamide D6 N oxide
7. Alpha-pyrrolidinovalerophenone
8. 11-Keto Loteprednol Etabonate
9. Dimenhydrinate Impurity D
10. 4-(Trifluoromethyl)phenyl propanol-1
11. 2-(Trifluoromethyl)phenyl propanol-1
12. bis(dimethylamino)boron chloride
13. Meclizine D8
14. 2-(2-aminothiazol-4-yl)-N-[2-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl) phenyl]acetamide
15. Glycopyrronium Bromide EP Impurity I
16. Paclitaxel N-Butyl Analog
17. Tizoxanide D4 Glucuronide
18. Tizoxanide D4 Sulfate
19. Oxfendazole
20. Nevirapine methyl D4


This page contains information about Ivosidenib Cas 1448347-49-6 and its Inhibitors.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."